Regeneron Pharmaceuticals continues to demonstrate robust performance driven by its flagship products, Eylea and Dupixent, amidst strong demand in the US market for biologics. The company's portfolio spans ophthalmology, oncology, and immunology, with significant exposure to the domestic healthcare sector. Key revenue drivers include Eylea, approved for retinal diseases, and Dupixent, co-developed with Sanofi, which targets atopic dermatitis, asthma, and COPD. In the fourth quarter of 2024, Regeneron reported substantial sales figures that highlight the strength of its core business. Eylea net sales reached $1.5 billion for the quarter, while high-dose Eylea HD gained traction in the market. Dupixent contributed significantly with Regeneron's share of global sales hitting $851 million. Additionally, oncology products like Libtayo contributed $241 million, reflecting expansion in immuno-oncology. The biotech sector is seeing rising demand for biologics driven by an aging US population, which increases the need for ophthalmology treatments. Regeneron competes with major players like Roche and Bristol Myers Squibb, leveraging its proprietary VelociSuite technologies and TRAP technology to accelerate protein engineering. With over 70% of revenue coming from domestic sales, the company aligns well with investor interests in US healthcare spending under Medicare and private insurance.